Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Joseph K. Park"'
Publikováno v:
Plastic and Reconstructive Surgery, Global Open, Vol 10, Iss 10S, Pp 154-155 (2022)
Externí odkaz:
https://doaj.org/article/cbe8915917b24cd5beec9f7e956ee5eb
Autor:
Marwan G Fakih, Scott Kopetz, Yasutoshi Kuboki, Tae Won Kim, Pamela N Munster, John C Krauss, Gerald S Falchook, Sae-Won Han, Volker Heinemann, Kei Muro, John H Strickler, David S Hong, Crystal S Denlinger, Gustavo Girotto, Myung-Ah Lee, Haby Henary, Qui Tran, Joseph K Park, Gataree Ngarmchamnanrith, Hans Prenen, Timothy J Price
Publikováno v:
The lancet oncology
Background Sotorasib, a specific, irreversible KRAS(G12C) protein inhibitor, has shown monotherapy clinical activity in KRAS(G12C)-mutated solid tumours, including colorectal cancer, in the CodeBreaK100 phase 1 trial. We aimed to investigate the acti
Autor:
Marwan G, Fakih, Scott, Kopetz, Yasutoshi, Kuboki, Tae Won, Kim, Pamela N, Munster, John C, Krauss, Gerald S, Falchook, Sae-Won, Han, Volker, Heinemann, Kei, Muro, John H, Strickler, David S, Hong, Crystal S, Denlinger, Gustavo, Girotto, Myung-Ah, Lee, Haby, Henary, Qui, Tran, Joseph K, Park, Gataree, Ngarmchamnanrith, Hans, Prenen, Timothy J, Price
Publikováno v:
The Lancet. Oncology. 23(1)
Sotorasib, a specific, irreversible KRASIn this single-arm, phase 2 trial, adult patients with KRASOn March 1, 2021, at data cutoff, 62 patients with KRASAlthough the 9·7% overall response rate did not reach the benchmark, oral administration of sot
Publikováno v:
European Journal of Haematology
Objectives To estimate the risk of thrombocytopenia in various cancers and chemotherapy regimens. Methods Structured patient‐level data from the Flatiron Health Electronic Health Record database were used to identify adult patients who received che
Autor:
Gerald A. Soff, Isabelle Ray-Coquard, Luis J. Marfil Rivera, Jon Fryzek, Megan Mullins, Lauren C. Bylsma, Joseph K. Park
Publikováno v:
PLOS ONE. 17:e0257673
Background Currently, there are no approved options to prevent or treat chemotherapy-induced thrombocytopenia (CIT). We performed a systematic literature review and meta-analysis on use of thrombopoietic agents for CIT. Patients and methods We search
Autor:
Joseph K. Park, Troy E. Barger, June Kim, David J. Kuter, Vibha Jawa, Andy Boshier, Daniel T. Mytych
Publikováno v:
British Journal of Haematology
Summary Antibodies to first‐generation recombinant thrombopoietin (TPO) neutralized endogenous TPO and caused thrombocytopenia in some healthy subjects and chemotherapy patients. The second‐generation TPO receptor agonist romiplostim, having no s
Autor:
Ramaswamy Govindan, J. Gutierrez, D. Kim, S.S. Ramalingam, Ferdinandos Skoulidis, M. Vincent, S. Jones, Martin Schuler, Bob T. Li, Qui Tran, Juergen Wolf, Vamsidhar Velcheti, Joseph K. Park, Benjamin Besse, F. Wilson, Grace K. Dy
Publikováno v:
Journal of Thoracic Oncology. 16:S1123
Publikováno v:
Blood. 136:15-16
Background: Acute Radiation Syndrome (ARS) is an acute illness caused by exposure to a high dose of penetrating radiation over a short period of time. Hematopoietic subsyndrome of ARS (HS-ARS) is characterized by dose dependent bone marrow depression
Autor:
Sergey Orlov, Kaoru Kubota, Jesús Cárdenas Sánchez, Jin-Hyoung Kang, Li Zhang, Alexander N. Fleishman, Joseph K. Park, Vera Hirsh, Konstantinos N. Syrigos, Carlos H. Barrios, Gary Thomas, David H. Henry, Cisio De Oliveira Brandao, Tilman Steinmetz, Dianne Tomita, Pere Gascón, Martin Šmakal, Rajnish Nagarkar, David Gordon
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 15(2)
This study evaluated noninferiority of darbepoetin alfa versus placebo for overall survival (OS) and progression-free survival (PFS) in anemic patients with NSCLC treated to a 12.0-g/dL hemoglobin (Hb) ceiling.Adults with stage IV NSCLC expected to r
Autor:
Arun Rangaswami, Christine Y Louie, Waldo Concepcion, Florette K. Hazard, Milton J. Finegold, Joseph K. Park
Publikováno v:
American Journal of Surgical Pathology. 40:998-1003
Hepatoblastoma is the most common malignant liver tumor in childhood. It has been associated with a variety of constitutional syndromes and gene mutations. However, there are very few reports of associations with pediatric hepatocellular adenomas (HC